Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.55 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507029 | 1.00 | NNMT (0.55) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL2843856 | 0.95 | NNMT (0.50) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL298258 | 0.89 | NNMT (0.53) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL16196089 | 0.82 | NNMT (0.47) | NNMTGRM5ASIC3ALOX5APFEN1 | |
| SCHEMBL2842156 | 0.81 | ASIC3 (0.42) | NNMTGRM5ASIC3PNMT | |
| SCHEMBL29809722 | 0.78 | NNMT (0.59) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL20731178 | 0.78 | NNMT (0.59) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL31000386 | 0.78 | NNMT (0.55) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL15951410 | 0.78 | NNMT (0.59) | NNMTGRM5ASIC3UHRF1ALOX5AP | |
| SCHEMBL1258214 | 0.78 | NNMT (0.55) | NNMTGRM5ASIC3UHRF1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4665339-A1 | INHIBITING ALPHA V BETA 8 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| WO-2014179186-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-06 | — | — | WO | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-30 | — | — | US | disclosed |
| WO-2014089324-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
| EP-1226138-A4 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1226138-A1 | FAB I INHIBITORS | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027103-A1 | FAB I INHIBITORS | SMITHKLINE BEECHAM CORPORATION (GB) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | NNMT 3299/4885GRM5 3992/4885ASIC3 4591/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | NNMT 703/4885GRM5 1935/4885ASIC3 3235/4885 |
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | NNMT 3137/4885GRM5 2961/4885ASIC3 4183/4885 |
| US-20140323468-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, REN | NNMT 637/4885GRM5 2877/4885ASIC3 2792/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | NNMT 1781/4885GRM5 1217/4885ASIC3 1114/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | NNMT 3299/4885GRM5 3992/4885ASIC3 4591/4885 |
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | NNMT 900/4885GRM5 1516/4885ASIC3 4181/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | NNMT 3137/4885GRM5 2961/4885ASIC3 4183/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | NNMT 3299/4885GRM5 3992/4885ASIC3 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.